Last updated: February 27, 2026
What is the Drug?
NDC 62011-0291 corresponds to Lomitapide, marketed under the brand name Juxtapid. It is an oral medication approved by the FDA for treating homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder characterized by extremely high LDL cholesterol levels resistant to conventional therapies.
Market Size and Adoption
Patient Population
The drug is approved for a rare condition with limited diagnoses:
- Estimated number of HoFH patients in the U.S.: approximately 1,300 to 3,000.
- Worldwide patients could total between 5,000 and 10,000 based on epidemiological studies.
Market Penetration
- As of 2022, approximately 20-25% of diagnosed patients are on lipid-lowering therapies, with Juxtapid capturing roughly 15-20% of this subgroup.
- Adoption remains constrained by physician familiarity, therapy costs, and the availability of newer agents such as PCSK9 inhibitors and lomitapide analogs.
Competitive Landscape
- Main competitors include Evolocumab (Repatha) and Alirocumab (Praluent), both PCSK9 inhibitors.
- Lomitapide's niche is primarily patients with severe HoFH unresponsive to other therapies.
Market Growth Factors
- Growing awareness and diagnosis of HoFH.
- Expanding use of combination lipid-lowering regimens.
- Potential approval of next-generation agents or formulations.
Price and Revenue Projections
Current Pricing
- Wholesale acquisition cost (WAC): approximately $9,200 per month, equaling $110,400 annually.
- Net prices after discounts or rebates are estimated at 30-40% lower.
Revenue Estimations (2023-2027)
| Year |
Estimated Patients |
Market Penetration |
Revenue (USD in millions) |
| 2023 |
400 (current) |
15% |
52 |
| 2024 |
600 |
20% |
125 |
| 2025 |
800 |
25% |
200 |
| 2026 |
1,000 |
30% |
300 |
| 2027 |
1,200 |
35% |
400 |
Assumption includes gradual adoption growth and incremental uptake.
Pricing Trends and Outlook
- BioPharma pricing strategies tend to stabilize; recent trends indicate minimal increases (2-3%) annually.
- Introduction of generic formulations might lower prices post-patent expiration (expected around 2028-2030).
Impact of Regulatory and Reimbursement Policies
- Insurance coverage, including Medicaid and Medicare, influences patient access.
- A shift towards value-based pricing could pressure margins.
- Expanded indications or combination therapy approval could influence market size and pricing strategies.
Regulatory and Policy Factors
- Patent expiry: Expected around 2028.
- New formulations or indications: Potential to extend patent life or expand market.
- Reimbursement landscape: Outpatient specialty drugs receive favorable coverage, but high prices can restrict utilization.
Key Risks and Opportunities
- Risks include emergence of effective generics, new competitive therapies, and regulatory changes.
- Opportunities exist in expanding indications, improving formulation delivery (e.g., injectable vs. oral), and increasing awareness among clinicians.
Summary
NDC 62011-0291, Lomitapide (Juxtapid), has a niche market within the rare disease HoFH. Its current price of approximately $110,400 annually per patient supports significant revenue projections, with potential to reach $400 million globally by 2027 if market penetration increases and pricing remains stable. The market faces risks from generics, newer therapies, and policy changes but benefits from the limited treatment landscape for severe HoFH.
Key Takeaways
- The drug targets a rare, high-value segment with limited competition.
- Current pricing supports high revenue levels; market growth relies on increased diagnosis and therapy acceptance.
- Patent expiration and potential biosimilar entry could significantly alter pricing and revenue in the next 5 years.
- Market expansion is possible through indication growth and formulation innovations.
FAQs
1. What are the primary competitors to Lomitapide?
PCSK9 inhibitors, including evolocumab and alirocumab, serve as main competitors for high LDL cholesterol management in severe cases, though they may not be direct substitutes for Lomitapide's niche in HoFH.
2. How does patent expiry impact market projections?
Patent expiration around 2028 could lead to generic Lomitapide formulations entering the market, potentially reducing prices by 50% or more, impacting revenues.
3. What factors influence reimbursement rates?
Insurance coverage policies, formulary placements, patient access programs, and value-based pricing models shape reimbursement outcomes for Lomitapide.
4. Are there any recent regulatory changes affecting Lomitapide?
No major FDA approvals or label modifications have been made recently. Future approvals for new indications or formulations could impact the market.
5. What is the potential for new therapies to replace Lomitapide?
Emerging therapies, including gene editing and novel lipid-lowering agents, could challenge Lomitapide's market share over the next decade, especially if they demonstrate superior efficacy or safety.
References
[1] U.S. Food and Drug Administration. (2013). Juxtapid (lomitapide) prescribing information.
